遅発型テイ・サックス病に対する遺伝子編集治療の基盤を確立(NIH scientists lay foundation for potential gene-editing therapy for late-onset Tay-Sachs)

ad

2025-08-15 アメリカ国立衛生研究所(NIH)

NIH研究チームは、成人発症型テイ=サックス病(LOTS)の治療に向けたゲノム編集の基盤を構築したと発表した。LOTSはHEXA遺伝子変異で酵素β-ヘキソサミニダーゼAが不足し神経障害を起こす希少疾患である。研究ではヒト細胞とマウスで点変異修正を行い、酵素活性を約10%改善、神経症状の進行抑制と寿命延長を確認した。わずかな活性回復でも患者の生活改善に有効とされ、臨床応用の可能性を示す。現在はAAVベクターなどを用いた中枢神経系への導入法を検討中で、NIH臨床センターでは25人のLOTS患者を対象に研究を進行。成果は他のリソソーム病への応用も期待される。

<関連情報>

CNS標的型ベース編集による主要な遅発性テイ・サックス変異の緩和がマウスで確認される CNS-targeted base editing of the major late-onset Tay-Sachs mutation alleviates disease in mice

Maria L. Allende, Mari Kono, Y. Terry Lee, Samantha M. Olmsted, Vienna Huso, Jenna Y. Bakir, Florencia Pratto, Cuiling Li, Colleen Byrnes, Galina Tuymetova, Hongling Zhu, Cynthia J. Tifft, and Richard L. Proia
The Journal of Clinical Investigation  Published: June 17, 2025
DOI:https://doi.org/10.1172/JCI183434

Graphical abstract

遅発型テイ・サックス病に対する遺伝子編集治療の基盤を確立(NIH scientists lay foundation for potential gene-editing therapy for late-onset Tay-Sachs)

Abstract

Late-onset Tay-Sachs (LOTS) disease is a lysosomal storage disorder most commonly caused by a point mutation (c.805G>A) in the HEXA gene encoding the α subunit of the lysosomal enzyme β-hexosaminidase A. LOTS manifests as a range of gradually worsening neurological symptoms beginning in young adulthood. Here, we explored the efficacy of an adenine base editor (ABE) programmed with an sgRNA to correct the HEXA c.805G>A mutation. Base editing in fibroblasts from a patient with LOTS successfully converted the pathogenic HEXA c.805A to G and partially restored β-hexosaminidase activity, with minimal genome-wide off-target editing. We generated a LOTS mouse model in which the mice exhibited decreased β-hexosaminidase activity, accumulation of GM2 ganglioside in the brain, progressive neurological manifestations, and reduced lifespan. Treatment of LOTS mice with the neurotropic virus AAV-PHP.eB carrying the ABE and an sgRNA targeting the LOTS point mutation partially corrected the c.805G>A mutation in the CNS, significantly increased brain β-hexosaminidase activity, and substantially reduced GM2 ganglioside accumulation in the brain. Moreover, the therapy delayed symptom onset and significantly extended median lifespan. These findings highlight the potential of base editing as an effective treatment for LOTS and its broader applicability to other lysosomal storage disorders.

細胞遺伝子工学
ad
ad
Follow
ad
タイトルとURLをコピーしました